

**ANNUAL REPORT  
OF THE LIQUIDITY CONTRACT  
WITH THE STOCKBROKER COMPANY GILBERT DUPONT**

Sartorius Stedim Biotech SA  
Z.I. Les Paluds  
Avenue de Jouques, CS 91051  
13781 Aubagne Cedex, France

Phone: +33.(0)4.42.84.56.00  
Fax: +33.(0)4.42.84.56.19  
www.sartorius-stedim.com

Aubagne, France | January 4, 2017

Under the liquidity contract concluded between Sartorius Stedim Biotech S.A. and the stockbroker Gilbert Dupont, the following assets appeared on the liquidity account at December 29, 2017:

- Number of shares: 2,178
- Liquidity account cash balance: € 475,474.10

For information, the following assets appeared on the half-year report of the liquidity contract of June 30, 2017:

- Number of shares: 0
- Liquidity account cash balance: € 0

It is also reminded that at the time of the implementation of the contract, November 6, 2017, the following assets were allocated to the liquidity account:

- €600,000.00

#### **A profile of Sartorius Stedim Biotech**

Sartorius Stedim Biotech is a leading international supplier of products and services that enable the biopharmaceutical industry to develop and manufacture drugs safely and efficiently. As a total solutions provider, Sartorius Stedim Biotech offers a portfolio covering nearly all steps of biopharmaceutical manufacture. The company focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. In 2016, the company employed approx. 4,700 people, and earned sales revenue of 1,051.6 million euros.

---

#### **Contact**

Mirko Koch  
Investor Relations  
+49(0)551.308.2402  
mirko.koch@sartorius.com